Advertisement

Annals of Hematology

, Volume 66, Issue 5, pp 247–249 | Cite as

MCNU in the treatment of essential thrombocythemia — a pilot study

  • H. Murakami
  • J. Tamura
  • M. Sawamura
Original Article

Summary

The efficacy of a single dose of MCNU 150 mg was evaluated in nine symptomatic patients with essential thrombocythemia (ET). As the platelet counts increased during the following 4 weeks, an extra dose of 100 mg of MCNU was administered to three patients. All patients had thrombotic or hemorrhagic complications. Seven patients responded. The mean platelet count decreased to below 1.0×1012/l within 5 weeks; it reached its lowest level (0.35×1012/l) at 6 weeks and became stable at less than 1.0×1012/l without further therapy for 12 weeks in all patients. Thrombotic and hemorrhagic complications ameliorated within 4 weeks in all patients. Our study indicates that MCNU acts as a platelet-reducing agent in patients with ET.

Key words

MCNU Essential thrombocythemia Platelet 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bellucci S, Janvier M, Tobelem G, Frandrin G, Charpak Y, Berger R, Boiron M (1986) Essential thrombocythemias. Cancer 58: 2440–2447Google Scholar
  2. 2.
    Bensinger TA, Logue GL, Rundles RW (1970) Hemorrhagic thrombocythemia: control of postsplenectomy thrombocytosis with melphalan. Blood 36: 61–69Google Scholar
  3. 3.
    Carter SK, Schabel FM jr, Broder LE, Johnston TP (1972) 1,3-Bis (2-chloroethyl)-1-nitrosourea (BCNU) and other nitrosoureas in cancer treatment: a review. Adv Cancer Res 16: 273–332Google Scholar
  4. 4.
    Case DC (1984) Therapy of essential thrombocythemia with thiotepa and chlorambucil. Blood 63: 51–54Google Scholar
  5. 5.
    Kutti J (1990) The management of thrombocytosis. Eur J Haematol 44: 81–88Google Scholar
  6. 6.
    Lofvenberg E, Wahlin A (1988) Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 41: 375–381Google Scholar
  7. 7.
    Masaoka T, Kimura K, Miyazaki T (1983) Phase-II study with methyl-6-[[[(2-chloroethyl) nitrosoamino] carbonyl] amino]-6-deoxy-α-D-glucopyranoside (MCNU) in hematological malignancies. Jpn J Cancer Chemother 10: 1518–1523Google Scholar
  8. 8.
    Masaoka T, Shibata H, Nagai K, Kanamaru A, Kitani T, Taniguchi N, Yonezawa T, Kawagoe H, Hirata M, Horiuchi A, Tsubaki K, Ohokubo H, Yasunaga K, Okamoto Y, Fujitake H, Sasada M, Nakamura T (1985) Clinical phase-II study of MCNU (ranimustine) in hematological malignant diseases. Chemotherapy 33: 271–278Google Scholar
  9. 9.
    Murphy S, Rosenthal DS, Weinfeld A, Briere J, Faguet GB, Knospe WH, Landaw SA, Laszlo J, Pisciotta AV, Tartaglia AP, Goldberg JD, Berk PD, Donovan PB, Wasserman LR (1982) Essential thrombocythemia: response during first year of therapy with melphalan and radioactive phosphorus: a Polycythemia Vera Study Group report. Cancer Treat Rep 66: 1495–1500Google Scholar
  10. 10.
    Murphy S, Hand H, Rosenthal D, Laszlo J (1986) Essential thrombocythemia: an interim report from the polycythemia Vera Study Group. Semin Hematol 23: 177–182Google Scholar
  11. 11.
    Panasci L, Fox P, Woolley P, Schein PS (1976) Pharmacologic studies of nonmyelosuppressive nitrosourea antitumor agents. Clin Res 24: 380AGoogle Scholar
  12. 12.
    Pauw BE de, van Bergen ANL, Haanen C, Steenbergen J (1985) Intermittent melphalan in the treatment of essential thrombocytosis with haemorrhage or thrombosis. Scand J Haematol 35: 448–450Google Scholar
  13. 13.
    Pearson TC (1991) Primary thrombocythemia: diagnosis and management. Br J Haematol 78: 145–148Google Scholar
  14. 14.
    Schafer AI (1991) Essential thrombocythemia. Prog Hemost Thromb 10: 69–96Google Scholar
  15. 15.
    Schein PS, Panasci L, Woolley P, Anderson T (1976) Pharmacology of chlorozotocin (NSC-178248), a new nitrosourea antitumor agent. Cancer Treat Rep 60: 801–805Google Scholar
  16. 16.
    Sekido S, Ninomiya K, Iwasaki M (1979) Biologic activity of MCNU: a new antitumor agent. Cancer Treat Rep 63: 961–970Google Scholar
  17. 17.
    Shimizu F, Arakawa M (1975) Effect of 3-[(4-amino-2-methyl-5-pyrimidinyl) methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride on lymphoid leukemia L-1210. Gan 66: 149–154Google Scholar
  18. 18.
    Takubo T, Namiuchi S, Ueda T, Shibata H, Nakamura H, Masaoka T, Yoshitake J, Ishigami S (1981) Effect of 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride (ACNU) on chronic myelocytic leukemia. Jpn J Cancer Chemother 8: 290–293Google Scholar
  19. 19.
    Wasserman TH (1974) Review of CCNU in clinical cancer therapy. Cancer Treat Rev 1: 131–151Google Scholar
  20. 20.
    Yoshikawa H (1978) AAAP therapy for relapse of acute leukemia. Jpn J Clin Hematol 19: 1332–1340Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • H. Murakami
    • 1
  • J. Tamura
    • 1
  • M. Sawamura
    • 1
  1. 1.Third Department of Internal MedicineGunma University School of MedicineGunmaJapan

Personalised recommendations